Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
C-Max (Cerebrolysin variant) vs Semax
An educational, source-based comparison of C-Max (Cerebrolysin variant) and Semax — how each peptide works, what it's researched for, and what to know before going deeper.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.
- BDNF/NGF upregulation
- Ischemic stroke recovery (clinical use in Russia)
- Attention and cognitive performance
- Anxiolytic-style effects
- • Approved as a medication in Russia; not FDA-approved in the US.
- • Most clinical literature is in Russian.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
| Semax | Semax in the treatment of ischemic stroke | Zhurnal Nevrologii i Psikhiatrii | 2018 | Reported improved neurological recovery scores in acute ischemic stroke. |
| Semax | Semax and its analogs in neuroprotection | Molecular Neurobiology | 2020 | Review of neurotrophic and antioxidant mechanisms. |
Side-effect & safety grid
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
- Approved as a medication in Russia; not FDA-approved in the US.
- Most clinical literature is in Russian.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
C-Max (Cerebrolysin variant) vs Semax — Key differences
- Class: C-Max (Cerebrolysin variant) is classified as Nootropic · Neurotrophic, while Semax is Nootropic · Neuroprotection.
- Primary research focus: C-Max (Cerebrolysin variant) — post-stroke cognitive recovery; Semax — bdnf/ngf upregulation.
- Tag: Cognition vs Cognition.